| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2011: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Research Abstract |
HTLV-1 is a causative agent of adult T-cell leukemia (ATL). Combination therapy containing arsenite has been shown to be effective to ATL patients.
In this study, we identified that USP10 as a binding partner of HTLV-1 Tax oncoprotein. We established USP10 knockout mice and its knockout cells. USP10 mutants in USP10-knockout cells indicated that USP10 inhibits arsenite-induced apoptosis by reducing ROS production by forming stress granules. USP10 interacted with G3BP1 and the interaction is critical for inhibition of apoptosis induced by arsenite. USP10 knockdown in T-cells augmented apoptosis induced by arsenite. Arsenite induced more apoptosis in ATL cells than HTLV-1-uninfected T-cell lines. Tax augmented arsenite-induced apoptosis in cells, and the augmentation needs the interaction with USP10. These results indicated that USP10 is a cellular protein controlling sensitivity of leukemia T-cells to arsenite therapy.
|
